Corcept Therapeutics Inc
A California drugmaker that tames the stress hormone cortisol, which the body pumps out in excess in some illnesses. Its best-known medicine, Korlym, treats Cushing's syndrome, a condition where too much cortisol causes high blood sugar and other troubles. Founded in 1998 by two Stanford psychiatrists, the company got its name from a mashup of "cortisol" and "concept." Its founding idea grew out of a Stanford researcher's hunch that the abortion pill mifepristone could also block cortisol's effects — a hunch that later became its flagship drug.
Granted 550.0K · Sold 239.0K
Granted 140.0K · Bought 100.0K
Granted 100.0K · Sold 10.0K
Granted 30.0K · Sold 20.0K
Granted 150.0K
Granted 214.0K · Sold 211.0K
Granted 148.5K
Granted 82.8K · Sold 80.0K
Granted 203.2K · Sold 209.0K
Granted 22.6K · Sold 25.0K
Granted 4.4K · Sold 4.4K
Granted 11.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Belanoff Joseph KChief Executive Officer, Director · 20 transactions | — | 6.36M | 550.0K | — | 239.0K |
| Baker G Leonard JrDirector · 8 transactions | +4.1% | 5.53M | 140.0K | 100.0K | — |
| Wilson James NDirector · 16 transactions | — | 2.82M | 100.0K | — | 10.0K |
| Mahoney David LDirector · 5 transactions | +1% | 2.55M | 30.0K | — | 20.0K |
| Hunt HazelChief Scientific Officer · 2 transactions | +39.3% | 255.4K | 150.0K | — | — |
| Maduck SeanSee Remarks · 37 transactions | — | 137.7K | 214.0K | — | 211.0K |
| Robb Gary CharlesChief Business Officer · 17 transactions | — | 125.0K | 148.5K | — | — |
| Mokari AtabakChief Financial Officer · 19 transactions | +299.1% | 56.1K | 82.8K | — | 80.0K |
| Guyer WilliamChief Development Officer · 39 transactions | — | 29.5K | 203.2K | — | 209.0K |
| Lyon Joseph DouglasSee Remarks · 24 transactions | -55.7% | 7.0K | 22.6K | — | 25.0K |
| Swisher Daniel N JRDirector · 4 transactions | 0% | 2.2K | 4.4K | — | 4.4K |
| Cannon GillianDirector · 3 transactions | — | 0 | 11.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -698.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.